Skip to content

H.Res. 803 · 119th Congress (2025–2027)

Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

CRS summary not yet available.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is H.Res. 803’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. John W. Rose (R-TN-6)
Cosponsors
11 cosponsors

7 original · 4 later

11 R

  1. Rep. Sheri Biggs (R-SC-3)· Original · Oct 10, 2025
  2. Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Oct 10, 2025
  3. Rep. Glenn Grothman (R-WI-6)· Original · Oct 10, 2025
  4. Rep. Diana Harshbarger (R-TN-1)· Original · Oct 10, 2025
  5. Rep. Harriet M. Hageman (R-WY)· Original · Oct 10, 2025
  6. Rep. Doug LaMalfa (R-CA-1)· Original · Oct 10, 2025
  7. Rep. Barry Moore (R-AL-1)· Original · Oct 10, 2025
  8. Rep. Robert B. Aderholt (R-AL-4)· Later · Oct 17, 2025
  9. Rep. Andy Harris (R-MD-1)· Later · Oct 28, 2025
  10. Rep. Ben Cline (R-VA-6)· Later · Nov 4, 2025
  11. Rep. Michael Guest (R-MS-3)· Later · Nov 4, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Submitted in House

    Document: Introduced in House

    Sources
  2. Latest

    Referred to committee

    Referred to the House Committee on Energy and Commerce.

    Sources

Committees

  1. HouseEnergy and CommerceReferred Oct 10, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (1)
  1. Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.

    Official title, Display title · Introduced in House